Gossamer Bio, Inc. (GOSS)
10.11
-0.67
(-6.22%)
USD |
NASDAQ |
Oct 07, 16:00
10.30
+0.19
(+1.88%)
After-Hours: 20:00
Gossamer Bio EPS Diluted (Quarterly) : -6.124 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.124 |
| March 31, 2026 | -15.94 |
| December 31, 2025 | -16.68 |
| September 30, 2025 | -16.92 |
| June 30, 2025 | -13.47 |
| March 31, 2025 | -12.92 |
| December 31, 2024 | -11.66 |
| September 30, 2024 | -10.89 |
| June 30, 2024 | 16.51 |
| March 31, 2024 | -14.86 |
| December 31, 2023 | -17.09 |
| September 30, 2023 | -16.59 |
| June 30, 2023 | -35.62 |
| March 31, 2023 | -41.46 |
| December 31, 2022 | -47.32 |
| September 30, 2022 | -52.08 |
| June 30, 2022 | -58.92 |
| March 31, 2022 | -60.91 |
| Date | Value |
|---|---|
| December 31, 2021 | -59.57 |
| September 30, 2021 | -64.26 |
| June 30, 2021 | -64.10 |
| March 31, 2021 | -62.24 |
| December 31, 2020 | -70.59 |
| September 30, 2020 | -64.02 |
| June 30, 2020 | -80.32 |
| March 31, 2020 | -69.90 |
| December 31, 2019 | -71.40 |
| September 30, 2019 | -63.86 |
| June 30, 2019 | -59.07 |
| March 31, 2019 | -71.84 |
| December 31, 2018 | -47.11 |
| September 30, 2018 | -60.00 |
| June 30, 2018 | -39.76 |
| March 31, 2018 | -31.62 |
| December 31, 2017 | -7.834 |
| September 30, 2017 | -0.3496 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| United Therapeutics Corp. | 7.271 |
| Arbutus Biopharma Corp. | -0.026 |
| Kura Oncology, Inc. | -0.769 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 16.90M |
| Revenue (Quarterly) | 9.238M |
| Total Expenses (Quarterly) | -7.662M |
| Enterprise Value | 48.91M |
| Gross Profit Margin (Quarterly) | 97.27% |
| Earnings Yield | -550.6% |
| Normalized Earnings Yield | -615.94 |